Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Liver Cancer: early-phase trial registry
2 of 3 indexed Metastatic Liver Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Metastatic Liver Cancer: 3 US clinical trials tracked, 2 recruiting.
Metastatic Liver Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Eureka Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-liver-cancer
OPEN 2 | RECR 67% | LATE 0 | EARLY 2 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Metastatic Liver Cancer lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Liver Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Liver Cancer is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
T-Cell Therapy (ECT204) in Adults With Advanced HCC
Eureka Therapeutics
NCT04864054
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Eureka Therapeutics
NCT04634357
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Techsomed Medical Technologies
NCT04970212
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Liver Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Liver Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Liver Cancer page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Metastatic Liver Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eureka Therapeutics sponsors the most Metastatic Liver Cancer trials on record, review their full trial history before evaluating a specific study. See Eureka Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Liver Cancer condition card totals 3 registered trials; most-linked intervention BioTraceIO Lite; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.